| Autor: |
Souan, Lina, Jazar, Husam Abu, Nashwan, Sura, Sughayer, Maher A. |
| Předmět: |
|
| Zdroj: |
Journal of Medical Virology; Nov2023, Vol. 95 Issue 11, p1-8, 8p |
| Abstrakt: |
Cytomegalovirus (CMV) is the most prevalent infection in recipients of hematopoietic stem cell transplant (HSCT). QuantiFERON‐CMV (QF‐CMV) and QuantiFERON‐Monitor (QFM) assays were used to test whether immune‐competent adult allogeneic HSCT recipients with CMV‐specific T cells can control CMV infection or reactivation. Our data demonstrated a significant correlation between CMV infection measured by CMV‐antigenemia test and QF‐CMV results, graft versus host disease (GvHD), and mortality rates. The QF‐CMV test revealed that CMV‐specific T cells with higher interferon‐γ (IFN‐γ) release were correlated with lower CMV infection rates. There was a significant negative association between QF‐CMV results, GvHD, and mortality rates. Data showed that a one‐unit rise in IFN‐γ was linked with a 12.7% reduction in GvHD and a 20.7% reduction in the mortality odds ratio. In addition, a negative correlation was found between QF‐M results and CMV infection, with the QFM test predicting protection against CMV infection by 1.9%. This is one of the few studies establishing the QF‐CMV test's predictive value for GvHD and mortality, its use to monitor HSCT patients for pre‐emptive therapy, and the use of the QFM test to predict CMV infection and mortality in HSCT patients. Thus, these assays could be utilized to optimize preventive and pre‐emptive therapy procedures to reduce transplant recipient adverse effects and posttransplant therapy costs. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text